GHRP-6 vs Hexarelin
Both GHRP-6 and Hexarelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRP-6
Evidence BGrowth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
View full GHRP-6 profile →Hexarelin
Evidence BHexarelin (HEX)
The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
View full Hexarelin profile →Side-by-Side
| Attribute | GHRP-6 | Hexarelin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved — research compound (cardioprotective signals investigated) |
| Typical Dose | 100–300 mcg, 1–3 times daily (subcutaneous) | 100 mcg, 1–2 times daily (subcutaneous) |
| Clinics Indexed | 64 | 41 |
| Categories | growth-hormone, appetite | growth-hormone, recovery |
Key reported benefits — GHRP-6
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Key reported benefits — Hexarelin
- ✓Strongest GH spike of GHRPs
- ✓Cardioprotective signals
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.